{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["136(22)"],"submitter":["Li S"],"pubmed_abstract":["<h4>Abstract</h4>Although antiretroviral therapy (ART) can reduce the viral load in the plasma to undetectable levels in human immunodeficiency virus (HIV)-infected individuals, ART alone cannot completely eliminate HIV due to its integration into the host cell genome to form viral reservoirs. To achieve a functional cure for HIV infection, numerous preclinical and clinical studies are underway to develop innovative immunotherapies to eliminate HIV reservoirs in the absence of ART. Early studies have tested adoptive T-cell therapies in HIV-infected individuals, but their effectiveness was limited. In recent years, with the technological progress and great success of chimeric antigen receptor (CAR) therapy in the treatment of hematological malignancies, CAR therapy has gradually shown its a"],"journal":["Chinese medical journal"],"pagination":["2658-2667"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10684145"],"repository":["biostudies-literature"],"pubmed_title":["Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure."],"pmcid":["PMC10684145"],"pubmed_authors":["Guo N","Su B","Zhang T","Li S","Wang H","Lambotte O"],"additional_accession":[]},"is_claimable":false,"name":"Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure.","description":"<h4>Abstract</h4>Although antiretroviral therapy (ART) can reduce the viral load in the plasma to undetectable levels in human immunodeficiency virus (HIV)-infected individuals, ART alone cannot completely eliminate HIV due to its integration into the host cell genome to form viral reservoirs. To achieve a functional cure for HIV infection, numerous preclinical and clinical studies are underway to develop innovative immunotherapies to eliminate HIV reservoirs in the absence of ART. Early studies have tested adoptive T-cell therapies in HIV-infected individuals, but their effectiveness was limited. In recent years, with the technological progress and great success of chimeric antigen receptor (CAR) therapy in the treatment of hematological malignancies, CAR therapy has gradually shown its a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-04-22T13:48:28.537Z","creation":"2025-04-06T00:49:25.031Z"},"accession":"S-EPMC10684145","cross_references":{"pubmed":["37927030"],"doi":["10.1097/CM9.0000000000002904"]}}